DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, announced today that its stockholders re-elected Carl J. Aschinger, Jr., Owen E. Johnson, M.D. and Fred B. Miller as Directors of the Company for terms ending at the 2011 Annual Meeting. In addition, Neoprobe’s stockholders approved an amendment to the Company’s 2002 Stock Incentive Plan to increase the number of shares issuable under the Plan from 5,000,000 to 7,000,000 shares.
